Literature DB >> 9703464

Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.

A H Li1, S Moro, N Melman, X D Ji, K A Jacobson.   

Abstract

The structure-activity relationships of 6-phenyl-1,4-dihydropyridine derivatives as selective antagonists at human A3 adenosine receptors have been explored (Jiang et al. J. Med. Chem. 1997, 39, 4667-4675). In the present study, related pyridine derivatives have been synthesized and tested for affinity at adenosine receptors in radioligand binding assays. Ki values in the nanomolar range were observed for certain 3,5-diacyl-2,4-dialkyl-6-phenylpyridine derivatives in displacement of [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)-5'-N-methylcarbamoyladenosine) at recombinant human A3 adenosine receptors. Selectivity for A3 adenosine receptors was determined vs radioligand binding at rat brain A1 and A2A receptors. Structure-activity relationships at various positions of the pyridine ring (the 3- and 5-acyl substituents and the 2- and 4-alkyl substituents) were probed. A 4-phenylethynyl group did not enhance A3 selectivity of pyridine derivatives, as it did for the 4-substituted dihydropyridines. At the 2- and 4-positions ethyl was favored over methyl. Also, unlike the dihydropyridines, a thioester group at the 3-position was favored over an ester for affinity at A3 adenosine receptors, and a 5-position benzyl ester decreased affinity. Small cycloalkyl groups at the 6-position of 4-phenylethynyl-1,4-dihydropyridines were favorable for high affinity at human A3 adenosine receptors, while in the pyridine series a 6-cyclopentyl group decreased affinity. 5-Ethyl 2, 4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate , 38, was highly potent at human A3 receptors, with a Ki value of 20 nM. A 4-propyl derivative, 39b, was selective and highly potent at both human and rat A3 receptors, with Ki values of 18.9 and 113 nM, respectively. A 6-(3-chlorophenyl) derivative, 44, displayed a Ki value of 7.94 nM at human A3 receptors and selectivity of 5200-fold. Molecular modeling, based on the steric and electrostatic alignment (SEAL) method, defined common pharmacophore elements for pyridine and dihydropyridine structures, e.g., the two ester groups and the 6-phenyl group. Moreover, a relationship between affinity and hydrophobicity was found for the pyridines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703464      PMCID: PMC3474377          DOI: 10.1021/jm980093j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.

Authors:  Y Karton; J L Jiang; X D Ji; N Melman; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1996-06-07       Impact factor: 7.446

2.  Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors.

Authors:  J Strickler; K A Jacobson; B T Liang
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

3.  Plasma and urinary metabolites of efonidipine hydrochloride in man.

Authors:  H Nakabeppu; M Asada; T Oda; Y Shinozaki; T Yajima
Journal:  Xenobiotica       Date:  1996-02       Impact factor: 1.908

4.  Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.

Authors:  Y C Kim; X D Ji; K A Jacobson
Journal:  J Med Chem       Date:  1996-10-11       Impact factor: 7.446

5.  Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.

Authors:  A M van Rhee; J L Jiang; N Melman; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1996-07-19       Impact factor: 7.446

6.  6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists.

Authors:  J L Jiang; A M van Rhee; N Melman; X D Ji; K A Jacobson
Journal:  J Med Chem       Date:  1996-11-08       Impact factor: 7.446

7.  125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.

Authors:  M E Olah; C Gallo-Rodriguez; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1994-05       Impact factor: 4.436

8.  Sustained activation of phospholipase D via adenosine A3 receptors is associated with enhancement of antigen- and Ca(2+)-ionophore-induced secretion in a rat mast cell line.

Authors:  H Ali; O H Choi; P F Fraundorfer; K Yamada; H M Gonzaga; M A Beaven
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

9.  Cationic [99mTcIII(DIARS)2(SR)2]+ complexes as potential myocardial perfusion imaging agents (DIARS = o-phenylenebis(dimethylarsine);SR- = thiolate).

Authors:  F Tisato; T Maina; L R Shao; M J Heeg; E Deutsch
Journal:  J Med Chem       Date:  1996-03-15       Impact factor: 7.446

10.  Adenosine A3 receptor stimulation and cerebral ischemia.

Authors:  D K Von Lubitz; R C Lin; P Popik; M F Carter; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1994-09-22       Impact factor: 4.432

View more
  37 in total

1.  Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors.

Authors:  X D Ji; K A Jacobson
Journal:  Drug Des Discov       Date:  1999-11

Review 2.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

3.  Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.

Authors:  Amanda Ford; Annie Castonguay; Martin Cottet; Joshua W Little; Zhoumou Chen; Ashley M Symons-Liguori; Timothy Doyle; Terrance M Egan; Todd W Vanderah; Yves De Koninck; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 4.  Medicinal chemistry of adenosine, P2Y and P2X receptors.

Authors:  Kenneth A Jacobson; Christa E Müller
Journal:  Neuropharmacology       Date:  2015-12-12       Impact factor: 5.250

5.  A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro.

Authors:  Anna Maria Pugliese; Elisabetta Coppi; Giampiero Spalluto; Renato Corradetti; Felicita Pedata
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 6.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Structure-activity relationships of 1,4-dihydropyridines that act as enhancers of the vanilloid receptor 1 (TRPV1).

Authors:  Eun Joo Roh; Jason M Keller; Zoltan Olah; Michael J Iadarola; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2008-08-26       Impact factor: 3.641

8.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors.

Authors:  Anna Maria Pugliese; Serena Latini; Renato Corradetti; Felicita Pedata
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

10.  Characterization of the A2B adenosine receptor from mouse, rabbit, and dog.

Authors:  John A Auchampach; Laura M Kreckler; Tina C Wan; Jason E Maas; Dharini van der Hoeven; Elizabeth Gizewski; Jayashree Narayanan; Garren E Maas
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.